Pharma & Biotech Global Week in Review 19 May 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

India and Brazil start WTO dispute proceedings against EU (Spicy IP) (Managing IP) (IP tango) (IP Watch) (Knowledge Ecology International)


The death of gene patents and communication IP value IP Think Tank podcast 1 Apr 2010 (IP Think Tank)

Proposals at WHO would boost drug safety, replace anti-counterfeiting taskforce (IP Watch)

Advocates back WHO resolution on Chagas with access to diagnosis, treatment (IP Watch)

Developing countries blast WHO report on IP, demand ‘credible’ approach (IP Watch)

Chan urges innovation, defends WHO flu response as new group approved (IP Watch)

WHO donors (US, Gates Foundation, UK, Norway, Canada, EC, GAVI and Roche): Setting the agenda for global public health? (Knowledge Ecology International)

Pharma nightmare: Falling off the patent cliff (IPKat)

Pharma executives slam Europe’s patent regime, while praising the US approach (IAM)

Putting open source to good use on the farm… (IPKat)

IFPMA developing world partnerships directory (IP Watch)

Counterfeit medicines in WTO dispute process, heating up at WHO (IP Watch)

Brazilian generic drug registration sets standard for ‘pipeline’ patents (IP Watch)

Colombia: Parallel import of pharmaceuticals (IP tango)

EU: India and Brazil start WTO dispute proceedings against EU (Spicy IP) (Managing IP) (IP tango) (Knowledge Ecology International)

EU: More on active implantable medical devices (SPC blog)

UK: More questions to the Court of Justice on the meaning of Article 3a and 3b of the SPC regulation (SPC blog)

UK: EPO Enlarged Board of Appeal decisions on patent eligibility of medical inventions – cases G2/08 (Dosage regime/Abbott Respiratory) and G1/07 (Treatment by surgery/Medi-Physics) (Ladas & Parry)

US: Healthcare Reform Bill presents significant opportunity for life science companies engaged in innovative research (Biotech Blog)

US: Docs at BIO: Steve Burrill’s State of the Biotechnology Industry Report 2010 (Patent Docs)

US: Kappos on the written description requirement – Ariad decision (271 Patent Blog)

US: Therasense, Inc. v. Becton, Dickinson & Co. briefing (Patent Docs) (Patent Docs)

US: Generic manufacturer ordered to produce ‘distribution strategy information’ for ANADA products: Bayer Healthcare LLC v. Norbrook Laboratories Ltd et al. (Docket Report)

US: CAFC dismisses case: HIF Bio, Inc. v. Yung Shin Pharmaceuticals Industrial Co. (Patent Docs)

US: CAFC affirms claim construction and corresponding summary judgment of non-infringement: Scantibodies Laboratory, Inc. v. Immutopics, Inc. (Patent Docs)


Actos and Actoplus Met (Pioglitazone) – Sandoz and Takeda settle patent dispute over Actos and Actoplus Met (Patent Docs)

Cozaar / Hyzaar (Losartan) – US: DC Circuit denies FDA’s petition for panel rehearing and rehearing en banc; Roxane/Apotex case continues (FDA Law Blog)

Entocort (Budesonide) – US: Teva reaches settlement agreement with AstraZeneca regarding generic Entocort capsules (SmartBrief)

Levaquin (Levafloxicin) – US: CAFC decision on whether separate enantiomers can have ‘first commercial marketing or use’ statuts for purpose of patent term extension: Ortho-McNeil Pharmaceutical, Inc. v. Lupin Pharmaceuticals, Inc. (Patent Docs)

Namenda (Memantine) – Orchid and Forest Labs settle Namenda infringement dispute (Patent Docs)

Provigil (Modafinil) – US: FTC wins preliminary battle in anti-trust case against Cephalon in relation to settlement of dispute over Provigil (IP Whiteboard)

Skelaxin (Metaxalone) – US: Outstanding Pre-FDAAA citizen petition causes FDA to rule against 180-day exclusivity forfeiture for generic Skelaxin (FDA Law Blog)

Solodyn (Minocycline hydrochloride) – US: Ranbaxy and Medicis settle Solodyn patent infringement dispute (Patent Docs)

%d bloggers like this: